As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies.
Top challenges impacting specialty pharmacy outcomes, and how health systems may achieve efficiencies and enhance performance for optimal outcomes.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
We need to equip pharmacists with technology that can help them to make impactful clinical interventions in the pharmacy and reimburse them for these services, which would help to address the provider shortage.
Months before the FTC sued the three largest pharmacy benefit managers, the CEO of Blue Shield of California battled its PBM - CVS Caremark - to bring a lower cost prostate cancer drug to its members.
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority.
We need to continue investing in research for early stage, localized prostate cancer, develop treatments that balance efficacy with quality-of-life considerations, ensure diverse representation in clinical trials, and listen to patients and incorporate their perspectives into treatment development and decision-making.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
To realize true, sustainable savings in total cost of care, the healthcare system needs to reconsider the support — or lack of support — it provides throughout patients’ medication experiences and the snowball effect that creates on a lifetime of healthcare costs.
New research was published this week analyzing how AI can be used to better manage medications for senior patients who use multiple medications simultaneously. It analyzed FeelBetter’s AI platform, which pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management.
Losing these retail medication outlets creates more than just pharmacy deserts. In many low-income and underserved areas, drugstores also serve as grocery stores and hubs for essential services, and hence their closures mean communities lose crucial access points for a variety of goods and services.
Any successful response to skyrocketing drug costs has to also actively manage medications at the individual level — just because someone can be on a medication doesn’t mean they should be.
PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies.
Healthcare organizations should work proactively with experts in the relevant domains to recognize and mitigate potential cybersecurity risks. Here's what to do to mitigate risk.
As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.
Despite the evidence of their positive impact, pharmacists today lack the ability to reliably bill for clinical services as healthcare providers. It is important that payers provision pharmacists, include them in networks, and enable reimbursement through traditional billing models.
This responsibility goes beyond mere box-ticking; it requires a deep, introspective examination of our own biases and blind spots and a genuine commitment to putting the well-being of the communities we serve first.
We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.